TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21990405

Group type: EXPERIMENTAL
Intervention: ABVD
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: MOPP/EBV/CAD (MEC)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Stanford V (StV)
Number of subjects: 76
Study: 18475028

Group type: EXPERIMENTAL
Intervention: Epidural injection of 1% ropivacaine and general anesthesia (epidural and general group, n=12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Epidural injection of saline and general anesthesia (general group, n=12)
Number of subjects: 24
Study: 16552408

Group type: EXPERIMENTAL
Intervention: Mail intervention
Number of subjects: 1801

Group type: EXPERIMENTAL
Intervention: Phone intervention
Number of subjects: 1801

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1801
Study: 12588386

Group type: EXPERIMENTAL
Intervention: Calcipotriol ointment
Number of subjects: 97

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 97
Study: 11326160

Group type: EXPERIMENTAL
Intervention: Cefotiam (1 g) and Metronidazole (0.5 g) intravenously 30 min before surgery
Number of subjects: 199

Group type: COMPARATOR
Intervention: Cefoxitin (2 g) intravenously 30 min before surgery
Number of subjects: 199
Study: 8781317

Group type: EXPERIMENTAL
Intervention: Interferon alfa (IFN‐alpha) 5 MU/m2 three times per week for 12 weeks
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Steroids plus interferon
Number of subjects: 61

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 61
Study: 1731672

Group type: EXPERIMENTAL
Intervention: Manual shaving
Number of subjects: 1980

Group type: COMPARATOR
Intervention: Electrical clipping
Number of subjects: 1980

Group type: EXPERIMENTAL
Intervention: Povidone-iodine solution (0.5%) irrigation
Number of subjects: 1980

Group type: COMPARATOR
Intervention: Saline solution irrigation
Number of subjects: 1980

Group type: EXPERIMENTAL
Intervention: Operative debridement with closed tube irrigation
Number of subjects: 1980

Group type: EXPERIMENTAL
Intervention: Primary open wound procedures followed by delayed muscular flap closures
Number of subjects: 1980

Group type: EXPERIMENTAL
Intervention: Open drainage
Number of subjects: 1980
Study: 6398725

Group type: EXPERIMENTAL
Intervention: Mesterolone
Number of subjects: 368

Group type: COMPARATOR
Intervention: Vitamin C
Number of subjects: 368
Study: 30098945

Group type: EXPERIMENTAL
Intervention: Social exclusion
Number of subjects: 85
Study: 26850805

Group type: EXPERIMENTAL
Intervention: 1000 mg of pomegranate extract daily for 30 days
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 25628416

Group type: EXPERIMENTAL
Intervention: Indapamide SR/Amlodipine
Number of subjects: 291

Group type: COMPARATOR
Intervention: Enalapril/Amlodipine
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Indapamide SR/Amlodipine (Amlodipine 10 mg subgroup)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Enalapril/Amlodipine (Amlodipine 10 mg subgroup)
Number of subjects: 291
Study: 24124708

Group type: EXPERIMENTAL
Intervention: Low-dose rFVIIa (20 µg/kg)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Conventional treatment (Control)
Number of subjects: 86
Study: 21905967

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg plus Amlodipine 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telmisartan 40-80 mg plus Amlodipine 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telmisartan plus Amlodipine combinations
Number of subjects: 0
Study: 17588688

Group type: EXPERIMENTAL
Intervention: L-arginine (7 gr/d)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 16536651

Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15454860

Group type: EXPERIMENTAL
Intervention: Continuous infusion of nicorandil (1.0 microg.kg(‐1).min(‐1))
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (no nicorandil)
Number of subjects: 24
Study: 11207038

Group type: EXPERIMENTAL
Intervention: Group 1: Cisplatin 20 mg/m(2) i.v. per day for 4 days, followed by Cy 2 g/m(2) i.v. on day 4; 12 partial responses (PR), 1 mixed response, 3 stable disease (SD).
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Group 2: Basic chemotherapy plus VP16 (50 mg/m(2) i.v. for 3 days) and Vincristine (1.5 mg/m(2) i.v. on days 1 and 6); 2 PR, 1 complete response (CR), and 2 very good partial responses (VGPR) in 5 patients treated at diagnosis.
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Combined therapy (CO-TH) with 131-I-MIBG (200 mCi) administered on day 10 after chemotherapy; no extra-medullary toxicity observed, mild myelosuppression in patients treated at diagnosis.
Number of subjects: 21
Study: 9398455

Group type: EXPERIMENTAL
Intervention: 0.125 mg triazolam (oral)
Number of subjects: 24
Study: 7991476

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (tissue plasminogen activator combined with intravenous heparin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Accelerated administration of tissue plasminogen activator (Activase) combined with intravenous heparin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 0
Study: 3283460

Group type: EXPERIMENTAL
Intervention: HIGH arterial lactate concentrations (perioperative infusion of Ringer's lactate)
Number of subjects: 19

Group type: COMPARATOR
Intervention: LOW arterial lactate concentrations (no exogenous lactate)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: HIGH arterial lactate concentrations
Number of subjects: 19
Study: 30257663

Group type: EXPERIMENTAL
Intervention: We Act - Together for Health intervention
Number of subjects: 548
Study: 26678956

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 3047

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 3047

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 3047

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3047
Study: 24331152

Group type: EXPERIMENTAL
Intervention: 180‐W GL XPS
Number of subjects: 281

Group type: COMPARATOR
Intervention: TURP
Number of subjects: 281
Study: 22101205

Group type: EXPERIMENTAL
Intervention: Usual care plus cognitive behavioural therapy (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 20100633

Group type: EXPERIMENTAL
Intervention: Titanium miniplates
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bioresorbable miniplates
Number of subjects: 40
Study: 18757660

Group type: EXPERIMENTAL
Intervention: Integrated multiple risk intervention delivered mainly during pregnancy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 16401159

Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 99

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 99
Study: 14713659

Group type: EXPERIMENTAL
Intervention: Natural-language search queries
Number of subjects: 7500
Study: 10754919

Group type: EXPERIMENTAL
Intervention: Telephone contact
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Home visit
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 8696720

Group type: EXPERIMENTAL
Intervention: Gemcitabine monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cisplatin and etoposide combination therapy
Number of subjects: 0
Study: 2071959

Group type: EXPERIMENTAL
Intervention: CPR 0.5 g (0.5 g twice a day for 14 days)
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: CPR 1.0 g (1.0 g twice a day for 14 days)
Number of subjects: 470

Group type: COMPARATOR
Intervention: CAZ (1.0 g twice a day for 14 days)
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: CPR 0.5 g (in patients with pneumonia)
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: CPR 1.0 g (in patients with pneumonia)
Number of subjects: 470

Group type: COMPARATOR
Intervention: CAZ (in patients with pneumonia)
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: CPR 0.5 g (in patients with chronic respiratory tract infection)
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: CPR 1.0 g (in patients with chronic respiratory tract infection)
Number of subjects: 470

Group type: COMPARATOR
Intervention: CAZ (in patients with chronic respiratory tract infection)
Number of subjects: 470
Study: 6140494

Group type: EXPERIMENTAL
Intervention: Tunnelled catheters
Number of subjects: 99

Group type: COMPARATOR
Intervention: Untunnelled catheters
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Nutrition nurse intervention
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Concurrent internal sepsis
Number of subjects: 99
Study: 31208475

Group type: EXPERIMENTAL
Intervention: Sour cream
Number of subjects: 47

Group type: COMPARATOR
Intervention: Butter, cheese, whipped cream, sour cream
Number of subjects: 47
Study: 29364754

Group type: EXPERIMENTAL
Intervention: Craniocervical flexion exercise (CFE), 30 minutes/day, 3 times a week for 8 weeks
Number of subjects: 41

Group type: COMPARATOR
Intervention: Isometric neck exercise (NIE), 30 minutes/day, 3 times a week for 8 weeks
Number of subjects: 41
Study: 26940483

Group type: EXPERIMENTAL
Intervention: Vaccination message focused on benefits to society
Number of subjects: 495

Group type: COMPARATOR
Intervention: Vaccination message focused on benefits to self
Number of subjects: 495

Group type: COMPARATOR
Intervention: Vaccination message focused on benefits to loved ones
Number of subjects: 495
Study: 28065217

Group type: EXPERIMENTAL
Intervention: EN+PN
Number of subjects: 120

Group type: COMPARATOR
Intervention: EN
Number of subjects: 120
Study: 23312052

Group type: EXPERIMENTAL
Intervention: IPE 4 g/day
Number of subjects: 229

Group type: COMPARATOR
Intervention: IPE 2 g/day
Number of subjects: 229

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229
Study: 19695922

Group type: EXPERIMENTAL
Intervention: Sodium glycididazole (700 mg/m² intravenous infusion 30 minutes before radiotherapy three times a week)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no sodium glycididazole)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sodium glycididazole
Number of subjects: 60
Study: 18554699

Group type: EXPERIMENTAL
Intervention: squeeze (n = 72)
Number of subjects: 151

Group type: COMPARATOR
Intervention: no squeeze (n = 79)
Number of subjects: 151
Study: 16038820

Group type: EXPERIMENTAL
Intervention: MVB (mesenteric vein bioprosthesis)
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Synthetic grafts
Number of subjects: 276

Group type: COMPARATOR
Intervention: INT (historic control group)
Number of subjects: 276
Study: 12439665

Group type: EXPERIMENTAL
Intervention: Orbscan
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Ultrasound Pachymetry
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography (OCT)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: OCT (after correction factor applied)
Number of subjects: 39
Study: 10329031

Group type: EXPERIMENTAL
Intervention: Pelvic radiotherapy (RT)
Number of subjects: 277

Group type: COMPARATOR
Intervention: No further treatment (NFT)
Number of subjects: 277
Study: 8602778

Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 291
Study: 1669033

Group type: EXPERIMENTAL
Intervention: CMI + LT3 (clomipramine 150 mg/day + LT3 50 micrograms/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: CMI + placebo (clomipramine 150 mg/day)
Number of subjects: 20
Study: 6365008

Group type: EXPERIMENTAL
Intervention: Clotrimazole troches (10 mg) three times a day
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo troches
Number of subjects: 84
Study: 30169855

Group type: EXPERIMENTAL
Intervention: Epidural analgesia (EP)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Paravertebral block (PVB)
Number of subjects: 4
Study: 29750362

Group type: EXPERIMENTAL
Intervention: Brief Motivational Intervention (BMI)
Number of subjects: 167
Study: 26762528

Group type: EXPERIMENTAL
Intervention: Varicella vaccine without human serum albumin (HSA)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Licensed varicella vaccine containing HSA
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 244
Study: 24485327

Group type: EXPERIMENTAL
Intervention: Experimental smartphone application
Number of subjects: 134

Group type: COMPARATOR
Intervention: W82GO Healthy Lifestyles intervention (usual care)
Number of subjects: 134
Study: 22332671

Group type: EXPERIMENTAL
Intervention: ALA-PDT (75 J cm(‐2) red light)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control area (chemical keratolytic treatment)
Number of subjects: 20
Study: 20382963

Group type: EXPERIMENTAL
Intervention: Multifactorial intervention in prevalent CKD patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment centre
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risk factors for progression of kidney failure and cardiovascular events
Number of subjects: 0
Study: 22379913

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Lornoxicam
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Morphine and Lornoxicam
Number of subjects: 38
Study: 16046230

Group type: EXPERIMENTAL
Intervention: Zinc oxide suspension
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zinc-containing toothpaste
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zinc-free toothpaste
Number of subjects: 0
Study: 11809159

Group type: EXPERIMENTAL
Intervention: Auditory oddball paradigm with button-press response
Number of subjects: 11
Study: 9510982

Group type: EXPERIMENTAL
Intervention: Josacine 500 mg tablets (2 tablets)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Josamycin solution (1 g drug, buffered at pH 4.0)
Number of subjects: 6
Study: 7985598

Group type: EXPERIMENTAL
Intervention: Nadolol therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mental stress testing
Number of subjects: 0
Study: 2686453

Group type: EXPERIMENTAL
Intervention: Triphasic oral contraceptives
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30533392

Group type: EXPERIMENTAL
Intervention: On-table extubation (OTE) group with sufentanil 0.15 µg/kg/h
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group with sufentanil 0.7-0.8 µg/kg/h
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: On-table extubation (OTE) group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 28298261

Group type: EXPERIMENTAL
Intervention: Agomelatine 10mg/day
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Agomelatine 25mg/day
Number of subjects: 412

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 412
Study: 25739769

Group type: EXPERIMENTAL
Intervention: Providing rapid diagnostic tests with realistic training
Number of subjects: 4603

Group type: COMPARATOR
Intervention: Control group (no rapid diagnostic tests)
Number of subjects: 4603
Study: 23850055

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 1452

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 1452

Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 1452

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg and 300 mg
Number of subjects: 1452
Study: 20885970

Group type: EXPERIMENTAL
Intervention: Secnidazole (2 g, once)
Number of subjects: 577

Group type: COMPARATOR
Intervention: Metronidazole (500 mg, b.i.d for seven days)
Number of subjects: 577
Study: 18978097

Group type: EXPERIMENTAL
Intervention: Diaphragm and lubricant gel provision
Number of subjects: 2040

Group type: COMPARATOR
Intervention: Condoms alone
Number of subjects: 2040
Study: 16357549

Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging
Number of subjects: 58
Study: 12954250

Group type: EXPERIMENTAL
Intervention: Bridging external fixation
Number of subjects: 85

Group type: COMPARATOR
Intervention: Plaster immobilization
Number of subjects: 85
Study: 12813842

Group type: EXPERIMENTAL
Intervention: Invitation to screening sigmoidoscopy with explanatory leaflet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Invitation to screening sigmoidoscopy with explanatory leaflet and option to discuss with general practitioner
Number of subjects: 0
Study: 8871834

Group type: EXPERIMENTAL
Intervention: IFN alpha 2 3.10(6) MU/3 times/week
Number of subjects: 20

Group type: COMPARATOR
Intervention: OH-chloroquine (OH-C) 6 mg/kg/daily
Number of subjects: 20
Study: 1613201

Group type: EXPERIMENTAL
Intervention: Intermittent Mandatory Pressure Release Ventilation (IMPRV)
Number of subjects: 16
Study: 6144316

Group type: COMPARATOR
Intervention: Pancuronium (loading dose 0.075 mg kg‐1, maintenance 0.015 mg kg‐1 every 42 min)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Vecuronium (loading dose 0.075 mg kg‐1, maintenance 0.015 mg kg‐1 every 12 min)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Continuous infusion of vecuronium (loading dose 0.075 mg kg‐1, continuous infusion 0.075 mg kg‐1 h‐1)
Number of subjects: 36
Study: 31474280

Group type: EXPERIMENTAL
Intervention: Belonging intervention (brief reading-writing exercise)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 86
Study: 26152558

Group type: EXPERIMENTAL
Intervention: Specialist smoking cessation services
Number of subjects: 1404

Group type: COMPARATOR
Intervention: Nonspecialist smoking cessation services
Number of subjects: 1404
Study: 25113425

Group type: EXPERIMENTAL
Intervention: Right nostril (Group R; n = 96)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Left nostril (Group L; n = 95)
Number of subjects: 191
Study: 22189698

Group type: EXPERIMENTAL
Intervention: Bubble CPAP
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional CPAP
Number of subjects: 32
Study: 22718435

Group type: COMPARATOR
Intervention: Rifampin
Number of subjects: 306

Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Doxycycline + Rifampin
Number of subjects: 306

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study: 18031501

Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 1% hydrocortisone cream
Number of subjects: 36

Group type: COMPARATOR
Intervention: Vehicle alone
Number of subjects: 36

Group type: COMPARATOR
Intervention: Untreated control area
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream and 1% hydrocortisone cream
Number of subjects: 36
Study: 15976800

Group type: EXPERIMENTAL
Intervention: High-dose glucose-insulin-potassium (GIK) infusion
Number of subjects: 940

Group type: COMPARATOR
Intervention: No GIK (Control)
Number of subjects: 940

Group type: EXPERIMENTAL
Intervention: GIK
Number of subjects: 940

Group type: COMPARATOR
Intervention: Control
Number of subjects: 940

Group type: COMPARATOR
Intervention: GIK and Control
Number of subjects: 940
Study: 12469639

Group type: EXPERIMENTAL
Intervention: Intravesical immunotherapy with imuron (6-week course) and maintenance therapy (3 weekly instillations each 3 months for the first year followed by once in 6 months)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Single monthly instillations
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Intravesical BCG-therapy
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Fever as a side effect
Number of subjects: 62
Study: 9804564

Group type: EXPERIMENTAL
Intervention: Subatmospheric pressure environment (‐30 to ‐40 mmHg) with heat (45‐46 degreesC, water‐perfused blanket) applied to a single forearm and hand.
Number of subjects: 16

Group type: COMPARATOR
Intervention: Heat alone applied to control subjects.
Number of subjects: 16
Study: 7614099

Group type: EXPERIMENTAL
Intervention: Olsalazine 0.5 g daily
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Olsalazine 1.25 g daily
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Olsalazine 2.0 g daily
Number of subjects: 162

Group type: COMPARATOR
Intervention: Sulphasalazine 2.0 g daily
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Olsalazine (all doses)
Number of subjects: 162
Study: 2615532

Group type: EXPERIMENTAL
Intervention: Combination of nystatin (NYS), pipemidic acid (PPA), and colistin sodium methanesulfonate (CLM)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Nystatin (NYS) alone
Number of subjects: 29
Study: 404962

Group type: COMPARATOR
Intervention: Ampicillin (AMP)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Carbenicillin (CB)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Both AMP and CB
Number of subjects: 86
Study: 30022457

Group type: EXPERIMENTAL
Intervention: Randomized AB phase design
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomization tests
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simulation study
Number of subjects: 0
Study: 27730703

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) of the subthalamic nucleus (STN)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Stimulation off state
Number of subjects: 7
Study: 25470228

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 325
Study: 22906113

Group type: EXPERIMENTAL
Intervention: Reappraisal strategies (importance and outcome)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Rumination
Number of subjects: 126

Group type: COMPARATOR
Intervention: No regulation instructions (control group)
Number of subjects: 126
Study: 21320227

Group type: EXPERIMENTAL
Intervention: Contingency group (employment-based reinforcement)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Prescription group (standard prescription)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 35
Study: 19961726

Group type: EXPERIMENTAL
Intervention: Admission blood glucose < 6.1 mmol/L
Number of subjects: 7446

Group type: EXPERIMENTAL
Intervention: Admission blood glucose 6.1 to 7.7 mmol/L
Number of subjects: 7446

Group type: EXPERIMENTAL
Intervention: Admission blood glucose > 13.0 mmol/L
Number of subjects: 7446

Group type: EXPERIMENTAL
Intervention: Admission blood glucose < 6.1 mmol/L in known diabetes
Number of subjects: 7446

Group type: EXPERIMENTAL
Intervention: Admission blood glucose 6.1 to 7.7 mmol/L in known diabetes
Number of subjects: 7446

Group type: EXPERIMENTAL
Intervention: Admission blood glucose > 13.0 mmol/L in known diabetes
Number of subjects: 7446
Study: 17333120

Group type: EXPERIMENTAL
Intervention: Active group (magnetic field of 1.5 mT)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (magnetic field at 0.05 mT)
Number of subjects: 31